Patents by Inventor Marine E. Bozdaganyan

Marine E. Bozdaganyan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220152116
    Abstract: A method of treating senescence in a subject can include applying a senoremediation drug treatment protocol to the subject in order to rescue one or more first cells in the subject, wherein the senoremediation drug treatment protocol is derived from a computational transcriptome analysis of the tissue or organ of the subject. The method can include applying a senolytic drug treatment protocol to the subject in order to remove one or more second cells in the subject. The method can include introducing stem cells into a tissue and/or organ of the subject in order to rejuvenate one or more tissue cells in the tissue and/or one or more organ cells in the organ. The method can include carrying out a reinforcement step that includes one or more actions that prevent further senescence or degradation of the tissue or organ.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 19, 2022
    Inventors: Aleksandr M. Aliper, Aleksandrs Zavoronkovs, Ivan Ozerov, Marine E. Bozdaganyan, Artem V. Artemov
  • Patent number: 11260078
    Abstract: A method of treating senescence in a subject can include applying a senoremediation drug treatment protocol to the subject in order to rescue one or more first cells in the subject, wherein the senoremediation drug treatment protocol is derived from a computational transcriptome analysis of the tissue or organ of the subject. The method can include applying a senolytic drug treatment protocol to the subject in order to remove one or more second cells in the subject. The method can include introducing stem cells into a tissue and/or organ of the subject in order to rejuvenate one or more tissue cells in the tissue and/or one or more organ cells in the organ. The method can include carrying out a reinforcement step that includes one or more actions that prevent further senescence or degradation of the tissue or organ.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: March 1, 2022
    Assignee: Insilico Medicine IP Limited
    Inventors: Aleksandr M. Aliper, Aleksandrs Zavoronkovs, Ivan Ozerov, Marine E. Bozdaganyan, Artem V. Artemov
  • Publication number: 20190030078
    Abstract: A method of treating senescence in a subject can include applying a senoremediation drug treatment protocol to the subject in order to rescue one or more first cells in the subject, wherein the senoremediation drug treatment protocol is derived from a computational transcriptome analysis of the tissue or organ of the subject. The method can include applying a senolytic drug treatment protocol to the subject in order to remove one or more second cells in the subject. The method can include introducing stem cells into a tissue and/or organ of the subject in order to rejuvenate one or more tissue cells in the tissue and/or one or more organ cells in the organ. The method can include carrying out a reinforcement step that includes one or more actions that prevent further senescence or degradation of the tissue or organ.
    Type: Application
    Filed: July 25, 2018
    Publication date: January 31, 2019
    Inventors: Aleksandr M. Aliper, Aleksandrs Zavoronkovs, Ivan Ozerov, Marine E. Bozdaganyan, Artem V. Artemov
  • Publication number: 20180225427
    Abstract: The present invention provides bioinformatics methods for predicting efficient protein inhibitors, compounds synthesized based on the methods and uses thereof, the method including identifying a BRD2 inhibitor by performing a pharmacophore-based search to produce a first plurality of candidate agents, applying a docking method to the first plurality of candidate agents to output a second plurality of candidate agents to provide at least one BRD2 inhibitor which are 2-acetyl-N,N,3-trisubstituted-5-[(substituted sulfonyl)substituted]imidazole-4-carboxamide and 1-{1,3,4-trisubstituted-5-[(substituted sulfonyl)substituted]-1H-pyrrol-2-yl}ethan-1-one, configured to inhibit the BRD2 protein.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 9, 2018
    Inventors: Alexander M. Aliper, Artem V. Artemov, Marine E. Bozdaganyan